Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2023 Dec 1;64(12):1880-1888. doi: 10.2967/jnumed.123.265715 Q19.12025
First-in-Humans PET Imaging of KRASG12C Mutation Status in Non-Small Cell Lung and Colorectal Cancer Patients Using [18F]PFPMD
用于非小细胞肺癌和结直肠癌患者的携带KRASG12C突变状态的[18F]PFPMD首次人体PET成像研究 翻译改进
Xiang Li 1, Jiajun Ye 1, Jingyi Wang 1, Zhiyong Quan 1, Guiyu Li 1, Wenhui Ma 1, Mingru Zhang 1, Weidong Yang 1, Junling Wang 1, Taoqi Ma 1, Fei Kang 2, Jing Wang 2
作者单位 +展开
作者单位
DOI: 10.2967/jnumed.123.265715 PMID: 37827842
摘要 Ai翻译
相关内容
-
Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer
携带KRAS G12C突变的非小细胞肺癌的真实世界预后
Wanyuan Cui et al.
Lung cancer (Amsterdam, Netherlands). 2020 Aug:146:310-317.
-
Correction to: Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer
纠正是：索托拉西布：KRAS G12C突变阳性非小细胞肺癌的回顾
Arnold Lee
Targeted oncology. 2023 Jan;18(1):177.
-
Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation
治疗带有KRAS G12C突变的非小细胞肺癌药物sotorasib
Xinting Zheng et al.
Drugs of today (Barcelona, Spain : 1998). 2022 Apr;58(4):175-185.
-
Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer
阿米拉韦：KRAS G12C突变阳性非小细胞肺癌中的疗效评估综述
Arnold Lee
Targeted oncology. 2022 Nov;17(6):727-733.
-
KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer
KRAS G12C突变是非小细胞肺癌培美曲塞治疗的预后不良标志物
Sehhoon Park et al.
The Korean journal of internal medicine. 2017 May;32(3):514-522.
-
KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)
德国前瞻性、观察性全国CRISP登记数据库中携带KRAS G12C突变的晚期非小细胞肺癌患者的真实世界队列（AIO-TRK-0315）
Martin Sebastian et al.
Lung cancer (Amsterdam, Netherlands). 2021 Apr:154:51-61.
-
[Pharmacological characteristics and clinical study results of the first RAS inhibitor sotorasib (LUMAKRAS®) for non-small cell lung cancer with KRAS G12C mutation]
[第一代KRAS-G12C抑制剂sotorasib（LUMAKRAS®）的药理学特征及其临床研究结果]
Hirotoshi Hoshiyama
Nihon yakurigaku zasshi. Folia pharmacologica Japonica. 2023;158(5):391-398.
-
KRAS G12C mutation in NSCLC in a small genetic center: insights into sotorasib therapy response potential
NSCLC中KRAS G12C突变的小型遗传中心：sotorasib治疗反应的启示
Metin Eser et al.
Scientific reports. 2024 Nov 4;14(1):26581.
